AU2004241949A1 - Disease prevention and vaccination prior to thymic reactivations - Google Patents

Disease prevention and vaccination prior to thymic reactivations Download PDF

Info

Publication number: AU2004241949A1
Authority: AU; Australia
Prior art keywords: patient; cells; sex steroid; thymus; hsc
Prior art date: 2003-04-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2004241949A

Other languages

English (en)

Inventor

Richard Boyd

Ann Patricia Chidgey

Gabrielle Lianne Goldberg

Jayne Suzanne Sutherland

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Norwood Immunology Ltd

Original Assignee

Norwood Immunology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-18

Filing date

2004-04-19

Publication date

2004-12-02

2003-04-18 Priority claimed from US10/418,747 external-priority patent/US20040018180A1/en

2003-04-18 Priority claimed from US10/419,068 external-priority patent/US20050002913A1/en

2003-04-18 Priority claimed from US10/418,727 external-priority patent/US20040013641A1/en

2003-04-18 Priority claimed from US10/419,066 external-priority patent/US20040037817A1/en

2003-12-30 Priority claimed from US10/749,118 external-priority patent/US20040265285A1/en

2003-12-30 Priority claimed from US10/748,831 external-priority patent/US20050020524A1/en

2003-12-30 Priority claimed from US10/748,450 external-priority patent/US20040241842A1/en

2003-12-30 Priority claimed from US10/749,122 external-priority patent/US20040259803A1/en

2004-04-19 Application filed by Norwood Immunology Ltd filed Critical Norwood Immunology Ltd

2004-12-02 Publication of AU2004241949A1 publication Critical patent/AU2004241949A1/en

Status Abandoned legal-status Critical Current

Links

230000007420 reactivation Effects 0.000 title claims description 40
230000002992 thymic effect Effects 0.000 title description 65
238000002255 vaccination Methods 0.000 title description 12
230000006806 disease prevention Effects 0.000 title description 3
210000004027 cell Anatomy 0.000 claims description 346
238000000034 method Methods 0.000 claims description 285
210000001744 T-lymphocyte Anatomy 0.000 claims description 248
239000003163 gonadal steroid hormone Substances 0.000 claims description 221
210000001541 thymus gland Anatomy 0.000 claims description 198
230000011664 signaling Effects 0.000 claims description 139
210000001185 bone marrow Anatomy 0.000 claims description 130
238000011282 treatment Methods 0.000 claims description 112
239000000427 antigen Substances 0.000 claims description 104
108091007433 antigens Proteins 0.000 claims description 102
102000036639 antigens Human genes 0.000 claims description 102
108090000623 proteins and genes Proteins 0.000 claims description 92
210000000130 stem cell Anatomy 0.000 claims description 89
230000001965 increasing effect Effects 0.000 claims description 87
230000001404 mediated effect Effects 0.000 claims description 81
239000003795 chemical substances by application Substances 0.000 claims description 74
206010028980 Neoplasm Diseases 0.000 claims description 70
210000002865 immune cell Anatomy 0.000 claims description 66
210000003719 b-lymphocyte Anatomy 0.000 claims description 64
210000004443 dendritic cell Anatomy 0.000 claims description 56
239000008280 blood Substances 0.000 claims description 50
208000015181 infectious disease Diseases 0.000 claims description 50
210000004369 blood Anatomy 0.000 claims description 49
230000001976 improved effect Effects 0.000 claims description 48
208000023275 Autoimmune disease Diseases 0.000 claims description 42
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
239000003102 growth factor Substances 0.000 claims description 41
229960005486 vaccine Drugs 0.000 claims description 41
239000000556 agonist Substances 0.000 claims description 39
241000700605 Viruses Species 0.000 claims description 36
201000010099 disease Diseases 0.000 claims description 36
230000028993 immune response Effects 0.000 claims description 36
239000003814 drug Substances 0.000 claims description 35
102000004127 Cytokines Human genes 0.000 claims description 34
108090000695 Cytokines Proteins 0.000 claims description 34
230000004044 response Effects 0.000 claims description 31
239000000126 substance Substances 0.000 claims description 28
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 27
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 27
241000725303 Human immunodeficiency virus Species 0.000 claims description 27
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 26
102000004169 proteins and genes Human genes 0.000 claims description 25
238000002512 chemotherapy Methods 0.000 claims description 24
210000003738 lymphoid progenitor cell Anatomy 0.000 claims description 23
230000002829 reductive effect Effects 0.000 claims description 23
201000011510 cancer Diseases 0.000 claims description 22
206010020751 Hypersensitivity Diseases 0.000 claims description 21
230000007815 allergy Effects 0.000 claims description 21
-1 Dioxalan derivatives Chemical compound 0.000 claims description 19
102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 19
108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 19
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 19
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 19
108010000817 Leuprolide Proteins 0.000 claims description 19
230000002708 enhancing effect Effects 0.000 claims description 19
241000894006 Bacteria Species 0.000 claims description 18
244000045947 parasite Species 0.000 claims description 18
208000024891 symptom Diseases 0.000 claims description 18
239000003112 inhibitor Substances 0.000 claims description 17
210000003643 myeloid progenitor cell Anatomy 0.000 claims description 17
230000001506 immunosuppresive effect Effects 0.000 claims description 16
210000003046 sporozoite Anatomy 0.000 claims description 16
108010002586 Interleukin-7 Proteins 0.000 claims description 15
208000026935 allergic disease Diseases 0.000 claims description 14
239000000051 antiandrogen Substances 0.000 claims description 14
241000233866 Fungi Species 0.000 claims description 13
230000002280 anti-androgenic effect Effects 0.000 claims description 13
230000001833 anti-estrogenic effect Effects 0.000 claims description 13
230000010076 replication Effects 0.000 claims description 13
206010062016 Immunosuppression Diseases 0.000 claims description 12
239000013566 allergen Substances 0.000 claims description 12
239000003098 androgen Substances 0.000 claims description 12
239000000328 estrogen antagonist Substances 0.000 claims description 12
229940046836 anti-estrogen Drugs 0.000 claims description 11
230000000779 depleting effect Effects 0.000 claims description 11
230000002458 infectious effect Effects 0.000 claims description 11
229960004338 leuprorelin Drugs 0.000 claims description 11
230000005855 radiation Effects 0.000 claims description 11
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 11
241000700584 Simplexvirus Species 0.000 claims description 10
238000000338 in vitro Methods 0.000 claims description 10
102000003812 Interleukin-15 Human genes 0.000 claims description 9
108090000172 Interleukin-15 Proteins 0.000 claims description 9
108010002350 Interleukin-2 Proteins 0.000 claims description 9
102000000588 Interleukin-2 Human genes 0.000 claims description 9
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 9
208000010668 atopic eczema Diseases 0.000 claims description 9
230000001939 inductive effect Effects 0.000 claims description 9
108010037003 Buserelin Proteins 0.000 claims description 8
LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 8
208000024780 Urticaria Diseases 0.000 claims description 8
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 8
208000006673 asthma Diseases 0.000 claims description 8
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 8
230000011132 hemopoiesis Effects 0.000 claims description 8
230000009385 viral infection Effects 0.000 claims description 8
102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 7
108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 7
108010069236 Goserelin Proteins 0.000 claims description 7
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 7
229940100994 interleukin-7 Drugs 0.000 claims description 7
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 7
210000001672 ovary Anatomy 0.000 claims description 7
239000000583 progesterone congener Substances 0.000 claims description 7
239000000849 selective androgen receptor modulator Substances 0.000 claims description 7
239000000333 selective estrogen receptor modulator Substances 0.000 claims description 7
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 6
108010021717 Nafarelin Proteins 0.000 claims description 6
201000008827 tuberculosis Diseases 0.000 claims description 6
241000711573 Coronaviridae Species 0.000 claims description 5
GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 5
108700012941 GNRH1 Proteins 0.000 claims description 5
102400000932 Gonadoliberin-1 Human genes 0.000 claims description 5
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 5
101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims description 5
108010023617 abarelix Proteins 0.000 claims description 5
AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 5
229960002184 abarelix Drugs 0.000 claims description 5
NGCGMRBZPXEPOZ-HBBGHHHDSA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)- Chemical compound CC(O)=O.C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NGCGMRBZPXEPOZ-HBBGHHHDSA-N 0.000 claims description 5
230000000172 allergic effect Effects 0.000 claims description 5
210000004556 brain Anatomy 0.000 claims description 5
210000000481 breast Anatomy 0.000 claims description 5
108700008462 cetrorelix Proteins 0.000 claims description 5
108700025485 deslorelin Proteins 0.000 claims description 5
229960005408 deslorelin Drugs 0.000 claims description 5
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 5
229960001442 gonadorelin Drugs 0.000 claims description 5
108700020746 histrelin Proteins 0.000 claims description 5
HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 5
230000001717 pathogenic effect Effects 0.000 claims description 5
YGGIRYYNWQICCP-LDRBRYNMSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylamino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydrox Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 YGGIRYYNWQICCP-LDRBRYNMSA-N 0.000 claims description 4
HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 4
241000701242 Adenoviridae Species 0.000 claims description 4
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 4
206010027654 Allergic conditions Diseases 0.000 claims description 4
241000712892 Arenaviridae Species 0.000 claims description 4
241000193830 Bacillus <bacterium> Species 0.000 claims description 4
241000702628 Birnaviridae Species 0.000 claims description 4
241000222122 Candida albicans Species 0.000 claims description 4
241000223205 Coccidioides immitis Species 0.000 claims description 4
201000004624 Dermatitis Diseases 0.000 claims description 4
241000194032 Enterococcus faecalis Species 0.000 claims description 4
241000186810 Erysipelothrix rhusiopathiae Species 0.000 claims description 4
241000711950 Filoviridae Species 0.000 claims description 4
208000004262 Food Hypersensitivity Diseases 0.000 claims description 4
241000590002 Helicobacter pylori Species 0.000 claims description 4
241000700739 Hepadnaviridae Species 0.000 claims description 4
241000700586 Herpesviridae Species 0.000 claims description 4
101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 claims description 4
241000701377 Iridoviridae Species 0.000 claims description 4
241000589248 Legionella Species 0.000 claims description 4
208000007764 Legionnaires' Disease Diseases 0.000 claims description 4
241000589902 Leptospira Species 0.000 claims description 4
102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 claims description 4
241000712464 Orthomyxoviridae Species 0.000 claims description 4
241000711504 Paramyxoviridae Species 0.000 claims description 4
241000701945 Parvoviridae Species 0.000 claims description 4
241000709664 Picornaviridae Species 0.000 claims description 4
241000700625 Poxviridae Species 0.000 claims description 4
108091000054 Prion Proteins 0.000 claims description 4
102000029797 Prion Human genes 0.000 claims description 4
241000702247 Reoviridae Species 0.000 claims description 4
241000712907 Retroviridae Species 0.000 claims description 4
241000711931 Rhabdoviridae Species 0.000 claims description 4
206010039085 Rhinitis allergic Diseases 0.000 claims description 4
241000191967 Staphylococcus aureus Species 0.000 claims description 4
241000193985 Streptococcus agalactiae Species 0.000 claims description 4
241000194049 Streptococcus equinus Species 0.000 claims description 4
241000193996 Streptococcus pyogenes Species 0.000 claims description 4
241000710924 Togaviridae Species 0.000 claims description 4
241000223997 Toxoplasma gondii Species 0.000 claims description 4
241000589904 Treponema pallidum subsp. pertenue Species 0.000 claims description 4
108700010877 adenoviridae proteins Proteins 0.000 claims description 4
201000010105 allergic rhinitis Diseases 0.000 claims description 4
229940030486 androgens Drugs 0.000 claims description 4
229960002719 buserelin Drugs 0.000 claims description 4
229940095731 candida albicans Drugs 0.000 claims description 4
229960003230 cetrorelix Drugs 0.000 claims description 4
210000001072 colon Anatomy 0.000 claims description 4
229940002533 cystorelin Drugs 0.000 claims description 4
235000020932 food allergy Nutrition 0.000 claims description 4
229960002913 goserelin Drugs 0.000 claims description 4
229960002193 histrelin Drugs 0.000 claims description 4
210000004072 lung Anatomy 0.000 claims description 4
229960003822 lutrelin Drugs 0.000 claims description 4
108700025096 meterelin Proteins 0.000 claims description 4
229960002333 nafarelin Drugs 0.000 claims description 4
RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 4
210000002307 prostate Anatomy 0.000 claims description 4
206010039083 rhinitis Diseases 0.000 claims description 4
229960004824 triptorelin Drugs 0.000 claims description 4
241000712461 unidentified influenza virus Species 0.000 claims description 4
241000228405 Blastomyces dermatitidis Species 0.000 claims description 3
241000193468 Clostridium perfringens Species 0.000 claims description 3
241001337994 Cryptococcus <scale insect> Species 0.000 claims description 3
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 3
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 3
241000228404 Histoplasma capsulatum Species 0.000 claims description 3
241000588915 Klebsiella aerogenes Species 0.000 claims description 3
241000588747 Klebsiella pneumoniae Species 0.000 claims description 3
241000186779 Listeria monocytogenes Species 0.000 claims description 3
241000588653 Neisseria Species 0.000 claims description 3
241000194017 Streptococcus Species 0.000 claims description 3
241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
239000003886 aromatase inhibitor Substances 0.000 claims description 3
229940092559 enterobacter aerogenes Drugs 0.000 claims description 3
208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
241000186227 Corynebacterium diphtheriae Species 0.000 claims description 2
241000224016 Plasmodium Species 0.000 claims description 2
208000003217 Tetany Diseases 0.000 claims description 2
241000589886 Treponema Species 0.000 claims description 2
229940046844 aromatase inhibitors Drugs 0.000 claims description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 6
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims 6
102000000704 Interleukin-7 Human genes 0.000 claims 6
229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims 6
102100024028 Progonadoliberin-1 Human genes 0.000 claims 6
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims 6
230000008472 epithelial growth Effects 0.000 claims 6
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 6
238000004393 prognosis Methods 0.000 claims 6
210000002950 fibroblast Anatomy 0.000 claims 5
241000186046 Actinomyces Species 0.000 claims 3
241000606125 Bacteroides Species 0.000 claims 3
241000194033 Enterococcus Species 0.000 claims 3
241000588650 Neisseria meningitidis Species 0.000 claims 3
241001478878 Streptobacillus Species 0.000 claims 3
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims 3
238000001678 elastic recoil detection analysis Methods 0.000 claims 3
208000038004 exacerbated respiratory disease Diseases 0.000 claims 3
201000004792 malaria Diseases 0.000 claims 3
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 claims 3
241000589876 Campylobacter Species 0.000 claims 2
241000193449 Clostridium tetani Species 0.000 claims 2
241000606790 Haemophilus Species 0.000 claims 2
241000588652 Neisseria gonorrhoeae Species 0.000 claims 2
241000223830 Plasmodium yoelii Species 0.000 claims 2
235000019568 aromas Nutrition 0.000 claims 2
241000606153 Chlamydia trachomatis Species 0.000 claims 1
201000007336 Cryptococcosis Diseases 0.000 claims 1
241000221204 Cryptococcus neoformans Species 0.000 claims 1
241000588914 Enterobacter Species 0.000 claims 1
241000605909 Fusobacterium Species 0.000 claims 1
241000605986 Fusobacterium nucleatum Species 0.000 claims 1
241000606768 Haemophilus influenzae Species 0.000 claims 1
241000228402 Histoplasma Species 0.000 claims 1
241000588748 Klebsiella Species 0.000 claims 1
241000186781 Listeria Species 0.000 claims 1
241000223960 Plasmodium falciparum Species 0.000 claims 1
229940038705 chlamydia trachomatis Drugs 0.000 claims 1
229940047650 haemophilus influenzae Drugs 0.000 claims 1
241000699670 Mus sp. Species 0.000 description 157
210000003958 hematopoietic stem cell Anatomy 0.000 description 140
210000000987 immune system Anatomy 0.000 description 59
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 55
238000010322 bone marrow transplantation Methods 0.000 description 49
238000004519 manufacturing process Methods 0.000 description 49
DPWSRXJWCYEGIV-CWMZTGDLSA-N acetic acid;n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxoprop Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 DPWSRXJWCYEGIV-CWMZTGDLSA-N 0.000 description 48
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 47
230000000694 effects Effects 0.000 description 44
230000000735 allogeneic effect Effects 0.000 description 40
210000000952 spleen Anatomy 0.000 description 39
210000001165 lymph node Anatomy 0.000 description 37
150000003431 steroids Chemical class 0.000 description 37
230000004043 responsiveness Effects 0.000 description 36
241001465754 Metazoa Species 0.000 description 35
230000007423 decrease Effects 0.000 description 32
238000002679 ablation Methods 0.000 description 31
230000009471 action Effects 0.000 description 29
210000004698 lymphocyte Anatomy 0.000 description 29
229940079593 drug Drugs 0.000 description 27
230000005764 inhibitory process Effects 0.000 description 27
230000008929 regeneration Effects 0.000 description 27
238000011069 regeneration method Methods 0.000 description 27
230000002093 peripheral effect Effects 0.000 description 26
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 25
102000005962 receptors Human genes 0.000 description 25
108020003175 receptors Proteins 0.000 description 25
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
230000015572 biosynthetic process Effects 0.000 description 22
235000018102 proteins Nutrition 0.000 description 22
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 21
230000006870 function Effects 0.000 description 21
230000014509 gene expression Effects 0.000 description 21
230000000638 stimulation Effects 0.000 description 21
239000000203 mixture Substances 0.000 description 20
210000001519 tissue Anatomy 0.000 description 20
210000000612 antigen-presenting cell Anatomy 0.000 description 19
108020004414 DNA Proteins 0.000 description 18
238000004458 analytical method Methods 0.000 description 18
230000035755 proliferation Effects 0.000 description 18
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
206010003694 Atrophy Diseases 0.000 description 17
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 17
230000037444 atrophy Effects 0.000 description 17
229940088597 hormone Drugs 0.000 description 17
239000005556 hormone Substances 0.000 description 17
230000002401 inhibitory effect Effects 0.000 description 17
238000011084 recovery Methods 0.000 description 17
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 16
238000002347 injection Methods 0.000 description 16
239000007924 injection Substances 0.000 description 16
241000282412 Homo Species 0.000 description 15
108700018351 Major Histocompatibility Complex Proteins 0.000 description 15
230000004913 activation Effects 0.000 description 15
239000005557 antagonist Substances 0.000 description 15
230000027455 binding Effects 0.000 description 15
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 15
230000007246 mechanism Effects 0.000 description 15
210000005259 peripheral blood Anatomy 0.000 description 15
239000011886 peripheral blood Substances 0.000 description 15
239000002243 precursor Substances 0.000 description 15
238000001959 radiotherapy Methods 0.000 description 15
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 15
239000013598 vector Substances 0.000 description 15
238000011161 development Methods 0.000 description 14
230000018109 developmental process Effects 0.000 description 14
238000009472 formulation Methods 0.000 description 14
210000000265 leukocyte Anatomy 0.000 description 14
210000002540 macrophage Anatomy 0.000 description 14
210000000056 organ Anatomy 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
230000003393 splenic effect Effects 0.000 description 14
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 13
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 13
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 13
230000008859 change Effects 0.000 description 13
229940011871 estrogen Drugs 0.000 description 13
239000000262 estrogen Substances 0.000 description 13
238000002560 therapeutic procedure Methods 0.000 description 13
108010033737 Pokeweed Mitogens Proteins 0.000 description 12
229960004397 cyclophosphamide Drugs 0.000 description 12
229940090044 injection Drugs 0.000 description 12
229960003604 testosterone Drugs 0.000 description 12
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 11
102000003946 Prolactin Human genes 0.000 description 11
108010057464 Prolactin Proteins 0.000 description 11
239000012634 fragment Substances 0.000 description 11
238000012239 gene modification Methods 0.000 description 11
230000005017 genetic modification Effects 0.000 description 11
235000013617 genetically modified food Nutrition 0.000 description 11
210000002149 gonad Anatomy 0.000 description 11
230000002265 prevention Effects 0.000 description 11
229940097325 prolactin Drugs 0.000 description 11
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 10
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 10
241000700588 Human alphaherpesvirus 1 Species 0.000 description 10
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 10
150000001875 compounds Chemical class 0.000 description 10
230000006378 damage Effects 0.000 description 10
102000015694 estrogen receptors Human genes 0.000 description 10
108010038795 estrogen receptors Proteins 0.000 description 10
238000001415 gene therapy Methods 0.000 description 10
210000000440 neutrophil Anatomy 0.000 description 10
150000007523 nucleic acids Chemical class 0.000 description 10
230000002062 proliferating effect Effects 0.000 description 10
230000009467 reduction Effects 0.000 description 10
238000006722 reduction reaction Methods 0.000 description 10
238000007920 subcutaneous administration Methods 0.000 description 10
229960000814 tetanus toxoid Drugs 0.000 description 10
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 9
102100021592 Interleukin-7 Human genes 0.000 description 9
102000008238 LHRH Receptors Human genes 0.000 description 9
108010021290 LHRH Receptors Proteins 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 9
210000004700 fetal blood Anatomy 0.000 description 9
210000003714 granulocyte Anatomy 0.000 description 9
239000012678 infectious agent Substances 0.000 description 9
206010022000 influenza Diseases 0.000 description 9
239000003446 ligand Substances 0.000 description 9
230000000670 limiting effect Effects 0.000 description 9
229940087857 lupron Drugs 0.000 description 9
102000039446 nucleic acids Human genes 0.000 description 9
108020004707 nucleic acids Proteins 0.000 description 9
230000002294 pubertal effect Effects 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
210000000601 blood cell Anatomy 0.000 description 8
230000037396 body weight Effects 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
238000000684 flow cytometry Methods 0.000 description 8
238000011134 hematopoietic stem cell transplantation Methods 0.000 description 8
230000003054 hormonal effect Effects 0.000 description 8
230000037361 pathway Effects 0.000 description 8
230000001817 pituitary effect Effects 0.000 description 8
102000040430 polynucleotide Human genes 0.000 description 8
108091033319 polynucleotide Proteins 0.000 description 8
239000002157 polynucleotide Substances 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
238000012546 transfer Methods 0.000 description 8
102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 7
230000000692 anti-sense effect Effects 0.000 description 7
229950004398 broxuridine Drugs 0.000 description 7
230000007812 deficiency Effects 0.000 description 7
239000002434 gonadorelin derivative Substances 0.000 description 7
230000004060 metabolic process Effects 0.000 description 7
210000000822 natural killer cell Anatomy 0.000 description 7
230000003716 rejuvenation Effects 0.000 description 7
102000005969 steroid hormone receptors Human genes 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
238000002054 transplantation Methods 0.000 description 7
208000030507 AIDS Diseases 0.000 description 6
102000053602 DNA Human genes 0.000 description 6
208000001388 Opportunistic Infections Diseases 0.000 description 6
108010085012 Steroid Receptors Proteins 0.000 description 6
238000010317 ablation therapy Methods 0.000 description 6
210000003995 blood forming stem cell Anatomy 0.000 description 6
229940047120 colony stimulating factors Drugs 0.000 description 6
208000024908 graft versus host disease Diseases 0.000 description 6
230000003053 immunization Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
230000000977 initiatory effect Effects 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
210000000581 natural killer T-cell Anatomy 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
238000002203 pretreatment Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
230000009696 proliferative response Effects 0.000 description 6
230000028327 secretion Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
241000701022 Cytomegalovirus Species 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 5
208000037357 HIV infectious disease Diseases 0.000 description 5
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 5
102100037852 Insulin-like growth factor I Human genes 0.000 description 5
102100039064 Interleukin-3 Human genes 0.000 description 5
108010002386 Interleukin-3 Proteins 0.000 description 5
206010060862 Prostate cancer Diseases 0.000 description 5
208000000236 Prostatic Neoplasms Diseases 0.000 description 5
210000001772 blood platelet Anatomy 0.000 description 5
210000000988 bone and bone Anatomy 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
210000002919 epithelial cell Anatomy 0.000 description 5
229960005309 estradiol Drugs 0.000 description 5
229930182833 estradiol Natural products 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
230000003394 haemopoietic effect Effects 0.000 description 5
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
238000002649 immunization Methods 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
230000035800 maturation Effects 0.000 description 5
230000002297 mitogenic effect Effects 0.000 description 5
210000000066 myeloid cell Anatomy 0.000 description 5
230000008488 polyadenylation Effects 0.000 description 5
229960003387 progesterone Drugs 0.000 description 5
239000000186 progesterone Substances 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
241000894007 species Species 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
210000001550 testis Anatomy 0.000 description 5
230000024664 tolerance induction Effects 0.000 description 5
108010059616 Activins Proteins 0.000 description 4
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
102000006771 Gonadotropins Human genes 0.000 description 4
108010086677 Gonadotropins Proteins 0.000 description 4
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
102100026818 Inhibin beta E chain Human genes 0.000 description 4
108091054438 MHC class II family Proteins 0.000 description 4
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
230000001594 aberrant effect Effects 0.000 description 4
239000000488 activin Substances 0.000 description 4
230000032683 aging Effects 0.000 description 4
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 4
230000005784 autoimmunity Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
230000007547 defect Effects 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
230000003828 downregulation Effects 0.000 description 4
210000003162 effector t lymphocyte Anatomy 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000002622 gonadotropin Substances 0.000 description 4
210000002443 helper t lymphocyte Anatomy 0.000 description 4
230000007124 immune defense Effects 0.000 description 4
230000036737 immune function Effects 0.000 description 4
239000007943 implant Substances 0.000 description 4
229940076264 interleukin-3 Drugs 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
210000005210 lymphoid organ Anatomy 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
238000007726 management method Methods 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
210000003289 regulatory T cell Anatomy 0.000 description 4
108091092562 ribozyme Proteins 0.000 description 4
229960001603 tamoxifen Drugs 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000014616 translation Effects 0.000 description 4
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
238000010600 3H thymidine incorporation assay Methods 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
102100032912 CD44 antigen Human genes 0.000 description 3
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 3
108010051696 Growth Hormone Proteins 0.000 description 3
208000037952 HSV-1 infection Diseases 0.000 description 3
208000009889 Herpes Simplex Diseases 0.000 description 3
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
108010004250 Inhibins Proteins 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
102000003814 Interleukin-10 Human genes 0.000 description 3
108090000174 Interleukin-10 Proteins 0.000 description 3
102000003815 Interleukin-11 Human genes 0.000 description 3
108090000177 Interleukin-11 Proteins 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
102000004058 Leukemia inhibitory factor Human genes 0.000 description 3
108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
102000043129 MHC class I family Human genes 0.000 description 3
108091054437 MHC class I family Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
102000003979 Mineralocorticoid Receptors Human genes 0.000 description 3
108090000375 Mineralocorticoid Receptors Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 3
102100030758 Sex hormone-binding globulin Human genes 0.000 description 3
102100038803 Somatotropin Human genes 0.000 description 3
210000000662 T-lymphocyte subset Anatomy 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000012190 activator Substances 0.000 description 3
210000004504 adult stem cell Anatomy 0.000 description 3
230000004075 alteration Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
229940044683 chemotherapy drug Drugs 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
238000009826 distribution Methods 0.000 description 3
210000001671 embryonic stem cell Anatomy 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
229960003399 estrone Drugs 0.000 description 3
230000035558 fertility Effects 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
230000009395 genetic defect Effects 0.000 description 3
230000002710 gonadal effect Effects 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
210000003297 immature b lymphocyte Anatomy 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
239000000893 inhibin Substances 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000004068 intracellular signaling Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
210000004153 islets of langerhan Anatomy 0.000 description 3
206010025135 lupus erythematosus Diseases 0.000 description 3
210000003071 memory t lymphocyte Anatomy 0.000 description 3
210000002901 mesenchymal stem cell Anatomy 0.000 description 3
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 3
230000001483 mobilizing effect Effects 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 3
229940085033 nolvadex Drugs 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
230000003071 parasitic effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
239000000047 product Substances 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000008439 repair process Effects 0.000 description 3
229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
210000002536 stromal cell Anatomy 0.000 description 3
238000007801 sublethal irradiation Methods 0.000 description 3
230000001629 suppression Effects 0.000 description 3
FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 3
238000013519 translation Methods 0.000 description 3
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
108010060191 3(17)-hydroxysteroid dehydrogenase Proteins 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
102000006306 Antigen Receptors Human genes 0.000 description 2
108010083359 Antigen Receptors Proteins 0.000 description 2
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
108010060434 Co-Repressor Proteins Proteins 0.000 description 2
102000008169 Co-Repressor Proteins Human genes 0.000 description 2
102100032768 Complement receptor type 2 Human genes 0.000 description 2
206010053138 Congenital aplastic anaemia Diseases 0.000 description 2
102400000739 Corticotropin Human genes 0.000 description 2
101800000414 Corticotropin Proteins 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
108091027757 Deoxyribozyme Proteins 0.000 description 2
201000009273 Endometriosis Diseases 0.000 description 2
241000709661 Enterovirus Species 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
101150095289 FGF7 gene Proteins 0.000 description 2
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 2
241000701806 Human papillomavirus Species 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102100039897 Interleukin-5 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
102100020880 Kit ligand Human genes 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
102100039564 Leukosialin Human genes 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
241001529936 Murinae Species 0.000 description 2
101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
102000006386 Myelin Proteins Human genes 0.000 description 2
108010083674 Myelin Proteins Proteins 0.000 description 2
201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
102000003505 Myosin Human genes 0.000 description 2
108060008487 Myosin Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
102000011931 Nucleoproteins Human genes 0.000 description 2
108010061100 Nucleoproteins Proteins 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
208000030852 Parasitic disease Diseases 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
108010039445 Stem Cell Factor Proteins 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
208000037913 T-cell disorder Diseases 0.000 description 2
101150052863 THY1 gene Proteins 0.000 description 2
229910052776 Thorium Inorganic materials 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
150000001242 acetic acid derivatives Chemical class 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
210000001789 adipocyte Anatomy 0.000 description 2
210000004100 adrenal gland Anatomy 0.000 description 2
238000011316 allogeneic transplantation Methods 0.000 description 2
229960002932 anastrozole Drugs 0.000 description 2
108010080146 androgen receptors Proteins 0.000 description 2
AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 2
229960005471 androstenedione Drugs 0.000 description 2
AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
230000000708 anti-progestin effect Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000003418 antiprogestin Substances 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
229940078010 arimidex Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
210000003651 basophil Anatomy 0.000 description 2
229960000997 bicalutamide Drugs 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229940097647 casodex Drugs 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
KFEFLCOCAHJBEA-ANRVCLKPSA-N cetrorelix acetate Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KFEFLCOCAHJBEA-ANRVCLKPSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
229960003624 creatine Drugs 0.000 description 2
239000006046 creatine Substances 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000003467 diminishing effect Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
229960000255 exemestane Drugs 0.000 description 2
229940087861 faslodex Drugs 0.000 description 2
230000008713 feedback mechanism Effects 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
229960002074 flutamide Drugs 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
229960000297 fosfestrol Drugs 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
229960002899 hydroxyprogesterone Drugs 0.000 description 2
208000031424 hyperprolactinemia Diseases 0.000 description 2
210000002861 immature t-cell Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000015788 innate immune response Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
210000002332 leydig cell Anatomy 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
229960004296 megestrol acetate Drugs 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
229960003248 mifepristone Drugs 0.000 description 2
239000002395 mineralocorticoid Substances 0.000 description 2
239000003607 modifier Substances 0.000 description 2
230000001400 myeloablative effect Effects 0.000 description 2
FSBTYDWUUWLHBD-UDXTWCDOSA-N nafarelin acetate hydrate Chemical compound O.CC(O)=O.C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 FSBTYDWUUWLHBD-UDXTWCDOSA-N 0.000 description 2
230000003448 neutrophilic effect Effects 0.000 description 2
229960002653 nilutamide Drugs 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
238000009806 oophorectomy Methods 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
210000001948 pro-b lymphocyte Anatomy 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
229940021993 prophylactic vaccine Drugs 0.000 description 2
230000004224 protection Effects 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000011476 stem cell transplantation Methods 0.000 description 2
230000035882 stress Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
229940086546 synarel Drugs 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
229940021747 therapeutic vaccine Drugs 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
229940033942 zoladex Drugs 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
RAJWOBJTTGJROA-UHFFFAOYSA-N (5alpha)-androstane-3,17-dione Natural products C1C(=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 RAJWOBJTTGJROA-UHFFFAOYSA-N 0.000 description 1
XZHKZJXZRWFLCJ-RKFIYKRSSA-N (8R,9S,10S,13R,14S,17R)-17-ethyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,17-dodecahydro-1H-cyclopenta[a]phenanthrene-15,16-dione Chemical compound [C@@H]12C(C([C@H](CC)[C@@]1(C)CC[C@H]1[C@H]2CCC2CCCC[C@]12C)=O)=O XZHKZJXZRWFLCJ-RKFIYKRSSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
IPVYMXZYXFFDGW-UHFFFAOYSA-N 1-methylpiperidin-4-ol;hydrochloride Chemical compound Cl.CN1CCC(O)CC1 IPVYMXZYXFFDGW-UHFFFAOYSA-N 0.000 description 1
VTHUYJIXSMGYOQ-KOORYGTMSA-N 17-hydroxyprogesterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 VTHUYJIXSMGYOQ-KOORYGTMSA-N 0.000 description 1
PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
101150110188 30 gene Proteins 0.000 description 1
GIYAQDDTCWHPPL-UHFFFAOYSA-N 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC GIYAQDDTCWHPPL-UHFFFAOYSA-N 0.000 description 1
BVPWJMCABCPUQY-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
102100033051 40S ribosomal protein S19 Human genes 0.000 description 1
239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
RAJWOBJTTGJROA-WZNAKSSCSA-N 5alpha-androstane-3,17-dione Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 RAJWOBJTTGJROA-WZNAKSSCSA-N 0.000 description 1
CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 1
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
241000701386 African swine fever virus Species 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102100032187 Androgen receptor Human genes 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
102000014654 Aromatase Human genes 0.000 description 1
108010078554 Aromatase Proteins 0.000 description 1
229940122815 Aromatase inhibitor Drugs 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
241001148536 Bacteroides sp. Species 0.000 description 1
208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
102100025221 CD70 antigen Human genes 0.000 description 1
210000003967 CLP Anatomy 0.000 description 1
241000589994 Campylobacter sp. Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
206010007275 Carcinoid tumour Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010008428 Chemical poisoning Diseases 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000025212 Constitutional neutropenia Diseases 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
241000186249 Corynebacterium sp. Species 0.000 description 1
241000709687 Coxsackievirus Species 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
102000003849 Cytochrome P450 Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
241000710829 Dengue virus group Species 0.000 description 1
201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
102100025537 ERI1 exoribonuclease 3 Human genes 0.000 description 1
102100025137 Early activation antigen CD69 Human genes 0.000 description 1
241001115402 Ebolavirus Species 0.000 description 1
241001466953 Echovirus Species 0.000 description 1
241001495410 Enterococcus sp. Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
102100031939 Erythropoietin Human genes 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
201000004939 Fanconi anemia Diseases 0.000 description 1
208000002633 Febrile Neutropenia Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
208000001287 Galactorrhea Diseases 0.000 description 1
206010017600 Galactorrhoea Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
206010048748 Graft loss Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
241000150562 Hantaan orthohantavirus Species 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
102100039869 Histone H2B type F-S Human genes 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
101000942297 Homo sapiens C-type lectin domain family 11 member A Proteins 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
101001056896 Homo sapiens ERI1 exoribonuclease 3 Proteins 0.000 description 1
101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 1
101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 1
102100025305 Integrin alpha-2 Human genes 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
102000000585 Interleukin-9 Human genes 0.000 description 1
108010036012 Iodide peroxidase Proteins 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
102000009875 Ki-67 Antigen Human genes 0.000 description 1
108010020437 Ki-67 Antigen Proteins 0.000 description 1
208000012565 Kostmann syndrome Diseases 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
206010024870 Loss of libido Diseases 0.000 description 1
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
102100022742 Lupus La protein Human genes 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
208000037093 Menstruation Disturbances Diseases 0.000 description 1
241000289419 Metatheria Species 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
101100091481 Mus musculus Trim21 gene Proteins 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
241000187484 Mycobacterium gordonae Species 0.000 description 1
241000186364 Mycobacterium intracellulare Species 0.000 description 1
241000186363 Mycobacterium kansasii Species 0.000 description 1
102000055324 Myelin Proteolipid Human genes 0.000 description 1
101710094913 Myelin proteolipid protein Proteins 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
102000007399 Nuclear hormone receptor Human genes 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000150218 Orthonairovirus Species 0.000 description 1
241000702244 Orthoreovirus Species 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
206010033888 Paraphilia Diseases 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
208000031845 Pernicious anaemia Diseases 0.000 description 1
241000713137 Phlebovirus Species 0.000 description 1
102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
YWYQTGBBEZQBGO-BERLURQNSA-N Pregnanediol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-BERLURQNSA-N 0.000 description 1
ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
102100025803 Progesterone receptor Human genes 0.000 description 1
108010083204 Proton Pumps Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
241000711798 Rabies lyssavirus Species 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
241000315672 SARS coronavirus Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
102000014744 Small Cytoplasmic Ribonucleoproteins Human genes 0.000 description 1
108010078688 Small Cytoplasmic Ribonucleoproteins Proteins 0.000 description 1
102000004598 Small Nuclear Ribonucleoproteins Human genes 0.000 description 1
108010003165 Small Nuclear Ribonucleoproteins Proteins 0.000 description 1
241001478880 Streptobacillus moniliformis Species 0.000 description 1
241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
102100027208 T-cell antigen CD7 Human genes 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
102100035268 T-cell surface protein tactile Human genes 0.000 description 1
210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000014267 Thyroid peroxidases Human genes 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
108090000253 Thyrotropin Receptors Proteins 0.000 description 1
102100029337 Thyrotropin receptor Human genes 0.000 description 1
IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
102000014034 Transcortin Human genes 0.000 description 1
108010011095 Transcortin Proteins 0.000 description 1
102000006290 Transcription Factor TFIID Human genes 0.000 description 1
108010083268 Transcription Factor TFIID Proteins 0.000 description 1
102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
241000700647 Variola virus Species 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
241000120645 Yellow fever virus group Species 0.000 description 1
QZBIKDNLZRFYMZ-KYOBJPNESA-N acetic acid;(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)- Chemical compound O.O.O.O.CC(O)=O.CC(O)=O.C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 QZBIKDNLZRFYMZ-KYOBJPNESA-N 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
239000000654 additive Substances 0.000 description 1
229940092229 aldactone Drugs 0.000 description 1
229940083712 aldosterone antagonist Drugs 0.000 description 1
239000002170 aldosterone antagonist Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
102000001307 androgen receptors Human genes 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
230000000781 anti-lymphocytic effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
239000003173 antianemic agent Substances 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940087620 aromasin Drugs 0.000 description 1
244000309743 astrovirus Species 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000007175 bidirectional communication Effects 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000003131 biological toxin Substances 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
230000008195 breast development Effects 0.000 description 1
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
229960001034 bromopride Drugs 0.000 description 1
229960005064 buserelin acetate Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229960001865 cetrorelix acetate Drugs 0.000 description 1
239000013000 chemical inhibitor Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000011651 chromium Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960001791 clebopride Drugs 0.000 description 1
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
229960003608 clomifene Drugs 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
JBIZUYWOIKFETJ-UHFFFAOYSA-N coumestan Chemical class O1C2=CC=CC=C2C2=C1C(C=CC=C1)=C1OC2=O JBIZUYWOIKFETJ-UHFFFAOYSA-N 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229940108605 cyclophosphamide injection Drugs 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
108091007930 cytoplasmic receptors Proteins 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940043239 cytotoxic antineoplastic drug Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
229960000766 danazol Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
229960000452 diethylstilbestrol Drugs 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
150000002012 dioxanes Chemical class 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
229960001253 domperidone Drugs 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
229950004203 droloxifene Drugs 0.000 description 1
JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
229960004199 dutasteride Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
210000000222 eosinocyte Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229960001208 eplerenone Drugs 0.000 description 1
JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
229950008385 estrone sulphate Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229940085363 evista Drugs 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229940083930 factrel Drugs 0.000 description 1
229940043168 fareston Drugs 0.000 description 1
229940087476 femara Drugs 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
229960004039 finasteride Drugs 0.000 description 1
229930003944 flavone Natural products 0.000 description 1
150000002213 flavones Chemical class 0.000 description 1
235000011949 flavones Nutrition 0.000 description 1
229960002690 fluphenazine Drugs 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
229960004421 formestane Drugs 0.000 description 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
229960002258 fulvestrant Drugs 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000002474 gonadorelin antagonist Substances 0.000 description 1
229960000290 gonadorelin diacetate tetrahydrate Drugs 0.000 description 1
229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 1
229940094892 gonadotropins Drugs 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
108090001052 hairpin ribozyme Proteins 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
210000005096 hematological system Anatomy 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
208000029570 hepatitis D virus infection Diseases 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
229940043650 hypothalamic hormone Drugs 0.000 description 1
239000000601 hypothalamic hormone Substances 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
108010067471 inhibin A Proteins 0.000 description 1
108010067479 inhibin B Proteins 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
229940074383 interleukin-11 Drugs 0.000 description 1
230000006662 intracellular pathway Effects 0.000 description 1
102000027411 intracellular receptors Human genes 0.000 description 1
108091008582 intracellular receptors Proteins 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
150000002515 isoflavone derivatives Chemical class 0.000 description 1
235000008696 isoflavones Nutrition 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
229960004145 levosulpiride Drugs 0.000 description 1
UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
229950007056 liarozole Drugs 0.000 description 1
229930013686 lignan Natural products 0.000 description 1
235000009408 lignans Nutrition 0.000 description 1
150000005692 lignans Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000000998 lymphohematopoietic effect Effects 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
229940090004 megace Drugs 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
231100000544 menstrual irregularity Toxicity 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000008747 mitogenic response Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000003039 myelosuppressive effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940029345 neupogen Drugs 0.000 description 1
230000000955 neuroendocrine Effects 0.000 description 1
210000000607 neurosecretory system Anatomy 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229940099637 nilandron Drugs 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
108091008685 nuclear receptors type I Proteins 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000003075 phytoestrogen Substances 0.000 description 1
208000010626 plasma cell neoplasm Diseases 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
229960002169 plerixafor Drugs 0.000 description 1
YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
210000004224 pleura Anatomy 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
235000013824 polyphenols Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960002847 prasterone Drugs 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
229960000249 pregnenolone Drugs 0.000 description 1
ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000007425 progressive decline Effects 0.000 description 1
229940072254 proscar Drugs 0.000 description 1
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000002629 repopulating effect Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
230000003938 response to stress Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000014102 seafood Nutrition 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
208000027390 severe congenital neutropenia 3 Diseases 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
108020003113 steroid hormone receptors Proteins 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229960004940 sulpiride Drugs 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
229940036197 supprelin Drugs 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000002381 testicular Effects 0.000 description 1
210000003684 theca cell Anatomy 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960005026 toremifene Drugs 0.000 description 1
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960000294 triptorelin pamoate Drugs 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
241000724775 unclassified viruses Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4257—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/43—Protozoan antigens
- A61K40/438—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/45—Bacterial antigens
- A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/48—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Zoology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Developmental Biology & Embryology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Genetics & Genomics (AREA)
AIDS & HIV (AREA)
Dermatology (AREA)
Reproductive Health (AREA)

AU2004241949A 2003-04-18 2004-04-19 Disease prevention and vaccination prior to thymic reactivations Abandoned AU2004241949A1 (en)

Applications Claiming Priority (19)

Application Number	Priority Date	Filing Date	Title
US10/418,747 US20040018180A1 (en)	1999-04-15	2003-04-18	Stimulation of thymus for vaccination development
US10/419,068		2003-04-18
US10/418,747		2003-04-18
US10/419,068 US20050002913A1 (en)	1999-04-15	2003-04-18	Hematopoietic stem cell gene therapy
US10/419,066		2003-04-18
US10/418,727 US20040013641A1 (en)	1999-04-15	2003-04-18	Disease prevention by reactivation of the thymus
US10/419,066 US20040037817A1 (en)	1999-04-15	2003-04-18	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US10/418,727		2003-04-18
US52700103P	2003-12-05	2003-12-05
US60/527,001		2003-12-05
US10/748,831		2003-12-30
US10/749,118 US20040265285A1 (en)	1999-04-15	2003-12-30	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US10/748,450		2003-12-30
US10/748,831 US20050020524A1 (en)	1999-04-15	2003-12-30	Hematopoietic stem cell gene therapy
US10/749,122		2003-12-30
US10/748,450 US20040241842A1 (en)	1999-04-15	2003-12-30	Stimulation of thymus for vaccination development
US10/749,122 US20040259803A1 (en)	1999-04-15	2003-12-30	Disease prevention by reactivation of the thymus
US10/749,118		2003-12-30
PCT/US2004/011921 WO2004103271A2 (fr)	2003-04-18	2004-04-19	Prevention de maladies et vaccination avant reactivation thymique

Publications (1)

Publication Number	Publication Date
AU2004241949A1 true AU2004241949A1 (en)	2004-12-02

Family

ID=33314639

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004241949A Abandoned AU2004241949A1 (en)	2003-04-18	2004-04-19	Disease prevention and vaccination prior to thymic reactivations

Country Status (6)

Country	Link
EP (2)	EP1620126A4 (fr)
JP (1)	JP2007518699A (fr)
KR (1)	KR20060022232A (fr)
AU (1)	AU2004241949A1 (fr)
CA (1)	CA2528521A1 (fr)
WO (2)	WO2004094599A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007518699A (ja) *	2003-04-18	2007-07-12	ノーウッド・イミュノロジー・リミテッド	胸腺再生前の病気の予防およびワクチン接種
CN100425288C (zh) *	2005-01-28	2008-10-15	北京金迪克生物技术研究所	鼻腔喷雾型流感病毒灭活疫苗及其制备方法
GB0519303D0 (en) *	2005-09-21	2005-11-02	Oxford Biomedica Ltd	Chemo-immunotherapy method
EP2288359B1 (fr) *	2008-04-21	2019-10-02	Tissue Regeneration Therapeutics Inc.	Cellules périvasculaires génétiquement modifiées de cordon ombilical humain pour une prophylaxie ou un traitement d'agents biologiques ou chimiques
US20110144032A1 (en) *	2008-08-08	2011-06-16	Christopher Hovens	Biological applications of steroid binding domains
US20110086051A1 (en) *	2009-10-08	2011-04-14	Dartmouth-Hitchcock Clinic	System and method for monitoring and optimizing immune status in transplant recipients
EP2906223A1 (fr) *	2012-10-15	2015-08-19	CHAMAELEO Pharma Bvba	Fosfestrol pour une utilisation dans le traitement curatif ou palliatif du cancer chez les mammifères femelles
WO2018134370A1 (fr)	2017-01-20	2018-07-26	Immune System Regulation Holding Ab	Nouveaux composés (immunorhélines)
CN110431147A (zh)	2017-01-20	2019-11-08	免疫系统调节控股有限公司	新化合物(免疫刺激肽-细胞内感染)
WO2018153961A1 (fr) *	2017-02-22	2018-08-30	Immune System Regulation Holding Ab	Hormones de libération des gonadotropines destinées à être utilisées en tant qu'adjuvants immunothérapeutiques

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPP977899A0 (en) *	1999-04-15	1999-05-13	Monash University	Improvement of t cell mediated immunity
US20040258672A1 (en) *	1999-04-15	2004-12-23	Monash University	Graft acceptance through manipulation of thymic regeneration
US20020086000A1 (en) *	1999-04-15	2002-07-04	Richard Boyd	Stimulation of thymus for vaccination development
AP2003002800A0 (en) *	2000-10-13	2003-06-30	Richard Boyd	Hematopoietic stem cell gene therapy
NZ525830A (en) *	2000-10-13	2005-07-29	Norwood Immunology Ltd	Disease prevention by reactivation of the thymus
JP2007518699A (ja) *	2003-04-18	2007-07-12	ノーウッド・イミュノロジー・リミテッド	胸腺再生前の病気の予防およびワクチン接種

2004
- 2004-04-19 JP JP2006532426A patent/JP2007518699A/ja not_active Withdrawn
- 2004-04-19 EP EP04785486A patent/EP1620126A4/fr not_active Withdrawn
- 2004-04-19 KR KR1020057019858A patent/KR20060022232A/ko not_active Withdrawn
- 2004-04-19 EP EP04759971A patent/EP1620545A4/fr not_active Withdrawn
- 2004-04-19 CA CA002528521A patent/CA2528521A1/fr not_active Abandoned
- 2004-04-19 AU AU2004241949A patent/AU2004241949A1/en not_active Abandoned
- 2004-04-19 WO PCT/US2004/011913 patent/WO2004094599A2/fr not_active Ceased
- 2004-04-19 WO PCT/US2004/011921 patent/WO2004103271A2/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2004094599A3 (fr)	2005-12-29
WO2004103271A3 (fr)	2005-11-24
EP1620545A2 (fr)	2006-02-01
JP2007518699A (ja)	2007-07-12
EP1620126A2 (fr)	2006-02-01
WO2004094599A2 (fr)	2004-11-04
CA2528521A1 (fr)	2004-12-02
EP1620126A4 (fr)	2007-07-04
KR20060022232A (ko)	2006-03-09
WO2004103271A2 (fr)	2004-12-02
EP1620545A4 (fr)	2007-07-04

Publication	Publication Date	Title
US20080279812A1 (en)	2008-11-13	Disease Prevention and Vaccination Prior to Thymic Reactivation
AU748443B2 (en)	2002-06-06	Costimulatory blockade and mixed chimerism in transplantation
AU734665B2 (en)	2001-06-21	Mixed chimerism and tolerance
CN100376288C (zh)	2008-03-26	T细胞介导的免疫的改善
US20050020524A1 (en)	2005-01-27	Hematopoietic stem cell gene therapy
AU2004241949A1 (en)	2004-12-02	Disease prevention and vaccination prior to thymic reactivations
CN1529607A (zh)	2004-09-15	T细胞疾病的治疗
US20040259803A1 (en)	2004-12-23	Disease prevention by reactivation of the thymus
CA2528503A1 (fr)	2004-11-04	Tolerance a implant avant la regeneration thymique
US20040241842A1 (en)	2004-12-02	Stimulation of thymus for vaccination development
US20040013641A1 (en)	2004-01-22	Disease prevention by reactivation of the thymus
US20080199495A1 (en)	2008-08-21	Stimulation of thymus for vaccination development
CN100406025C (zh)	2008-07-30	性类固醇拮抗剂和性类固醇激动剂的制药用途
US20050042679A1 (en)	2005-02-24	Diagnostic indicator of thymic function
US20070274946A1 (en)	2007-11-29	Tolerance to Graft Prior to Thymic Reactivation
US20040265285A1 (en)	2004-12-30	Normalization of defective T cell responsiveness through manipulation of thymic regeneration
ZA200509362B (en)	2007-03-28	Disease prevention and vaccination prior to thymic reactivations
US20040018180A1 (en)	2004-01-29	Stimulation of thymus for vaccination development
CN1809379A (zh)	2006-07-26	先于胸腺再活化的疾病预防和疫苗接种
ZA200509363B (en)	2007-04-25	Tolerance to graft prior to thymic regeneration
JP2004511495A (ja)	2004-04-15	造血幹細胞遺伝子療法
US20050215479A1 (en)	2005-09-29	Diagnostic indicator of thymic function
CN1479638A (zh)	2004-03-03	通过控制胸腺的再生改善移植物的接受度
US20050002913A1 (en)	2005-01-06	Hematopoietic stem cell gene therapy
US20040037816A1 (en)	2004-02-26	Graft acceptance through manipulation of thymic regeneration

Legal Events

Date	Code	Title	Description
2009-11-12	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application